A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes

Phase 1 Completed 28 enrolled Novo Nordisk A/S

RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the exposure of NN5401 (insulin degludec/insulin aspart) in young adults and elderly subjects with type 1 diabetes mellitus.

Timeline

Start: 2010-08
Primary completion: 2010-11
Completion: 2010-11

Publications

Results Brunner M, Pieber T, Korsatko S, Kojzar H, Svendsen AL, Haahr H. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes. Drugs Aging. 2015 Jul;32(7):583-90. doi: 10.1007/s40266-015-0272-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IDegAsp	Protein / enzyme biologic	0.5 iu/kg	Subcutaneous
Subject	biphasic insulin aspart 30	Protein / enzyme biologic	0.5 iu/kg	Subcutaneous

A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes

Summary

Timeline

Publications

Drugs

Indications